ADPT
Bearish signalScored 2026-10-27 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
Adaptive Biotechnologies Corporation
- Nom
- Adaptive Biotechnologies Corporation
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $4.0B
- Employés
- 624
- PDG
- Chad Robins
- Site web
- https://www.adaptivebiotech.com
- Marché
- —
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 764 969 titres (~19 024 608,06 $ US)
- Insiders
- OWEN KATEY EINTERZHERSHBERG ROBERTROBINS CHAD MNEUPERT PETER M
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$6,403,686
Avg sell (VWAP, 90d window) $26.14 vs last close $26.27 (+0.5%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$3,509,619 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-26
- Liquidity
- Liquid $53,847,828/day · 20d vol
- Last synced
-
2026-10-27 02:52:58
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-21 | RUBINSTEIN JULIE | Sell · S | 5,882 | $25.57 | $150,403 | Form 4 |
| 2026-10-20 | RUBINSTEIN JULIE | Sell · S | 100 | $24.85 | $2,485 | Form 4 |
| 2026-10-19 | RUBINSTEIN JULIE | Sell · S | 11,881 | $24.05 | $285,738 | Form 4 |
| 2026-10-16 | RUBINSTEIN JULIE | Sell · S · 10b5-1 | 300 | $25.45 | $7,635 | Form 4 |
| 2026-10-15 | RUBINSTEIN JULIE | Sell · S · 10b5-1 | 11,881 | $25.61 | $304,272 | Form 4 |
| 2026-10-14 | RUBINSTEIN JULIE | Sell · S · 10b5-1 | 5,100 | $25.82 | $131,682 | Form 4 |
| 2026-10-13 | RUBINSTEIN JULIE | Sell · S · 10b5-1 | 11,881 | $25.50 | $302,966 | Form 4 |
| 2026-10-12 | RUBINSTEIN JULIE | Sell · S · 10b5-1 | 2,700 | $26.07 | $70,389 | Form 4 |
| 2026-10-09 | RUBINSTEIN JULIE | Sell · S · 10b5-1 | 11,881 | $26.41 | $313,777 | Form 4 |
| 2026-10-08 | RUBINSTEIN JULIE | Sell · S · 10b5-1 | 11,881 | $25.66 | $304,866 | Form 4 |
| 2026-10-07 | RUBINSTEIN JULIE | Sell · S · 10b5-1 | 11,881 | $26.40 | $313,658 | Form 4 |
| 2026-10-06 | BOBULSKY SUSAN | Sell · S · 10b5-1 | 6,444 | $30.00 | $193,320 | Form 4 |
| 2026-10-06 | RUBINSTEIN JULIE | Sell · S · 10b5-1 | 499 | $30.53 | $15,234 | Form 4 |
| 2026-10-05 | RUBINSTEIN JULIE | Sell · S · 10b5-1 | 5,182 | $29.67 | $153,750 | Form 4 |
| 2026-10-02 | RUBINSTEIN JULIE | Sell · S · 10b5-1 | 11,881 | $28.13 | $334,213 | Form 4 |
| 2026-10-01 | LO FRANCIS | Sell · S · 10b5-1 | 18,698 | $28.61 | $534,950 | Form 4 |
| 2026-10-01 | RUBINSTEIN JULIE | Sell · S · 10b5-1 | 5,800 | $28.56 | $165,648 | Form 4 |
| 2026-09-16 | LO FRANCIS | Sell · S · 10b5-1 | 7,869 | $28.57 | $224,817 | Form 4 |
| 2026-09-15 | BOBULSKY SUSAN | Sell · S · 10b5-1 | 1,195 | $27.00 | $32,265 | Form 4 |
| 2026-08-26 | OWEN KATEY EINTERZ | Sell · S | 9,615 | $26.00 | $249,990 | Form 4 |
| 2026-08-18 | HERSHBERG ROBERT | Sell · S | 15,664 | $24.41 | $382,358 | Form 4 |
| 2026-08-18 | ROBINS CHAD M | Sell · S | 204 | $25.14 | $5,129 | Form 4 |
| 2026-08-17 | NEUPERT PETER M | Sell · S | 69,690 | $25.16 | $1,753,400 | Form 4 |
| 2026-08-17 | ROBINS CHAD M | Sell · S | 2,525 | $25.57 | $64,564 | Form 4 |
| 2026-08-10 | BOBULSKY SUSAN | Sell · S · 10b5-1 | 3,000 | $25.00 | $75,000 | Form 4 |
| 2026-07-30 | BOBULSKY SUSAN | Sell · S · 10b5-1 | 1,299 | $24.00 | $31,176 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2022-02-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-10-27 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
ADPT combines a weak catalyst score (20) driven by heavy insider selling ($19M+, zero buys) with fragile fundamentals — persistent negative operating cash flow, high leverage (D/E 1.28), and negative interest coverage…
The first sentence of the analysis written for ADPT on 2026-10-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Unavailable or mixed. Current ratio 3.34 · operating margin -21% — readings disagree
Suggested stop 22.85, nearest stored support minus 0.5 ATR(13.0% under the last close). Reward/risk to the next stored resistance is 1.08. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-23 Alger Small Cap Focus Fund Q3 2026 Portfolio Update Forte Biosciences Inc., Twist Bioscience Corp., and Adaptive Biotechnologies Corp., were among the top contributors to performance. Cardinal Infrastructure Group, Inc., RBC Bearings Incorporated, and VSE Corporation were among the top detractors from performance. VSE Corporation shares detracted from performance during the quarter despite strong revenue growth, record profitability, and an improved full-year outlook.
- 2026-10-19 Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $304,272.41 in Stock Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) COO Julie Rubinstein sold 11,881 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $25.61, for a total transaction of $304,272.41. Following the sale, the chief operating officer directly owned 377,802 shares in the
- 2026-10-14 Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026 SEATTLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2026 after market close on Wednesday, November 4, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- 2026-10-12 Adaptive Biotechnologies Corp (ADPT) Stock Down 3.5% but Still Overvalued -- GF Score: 68/100 On October 12, 2026, Adaptive Biotechnologies Corp (ADPT) shares fell 3.5%, currently trading at $25.57. The stock has seen significant volatility, with a 52-we
- 2026-10-12 Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Rated “Moderate Buy” by Sell-Side Brokerages Shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) have received an average rating of "Moderate Buy" from the eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy
- 2026-10-06 Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 52-Week High – Still a Buy? Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $30.10 and last traded at $30.3490, with a volume of 2895 shares trading hands. The stock had previously closed at $29.84. Analyst Ratings Changes Several research firms have commented on ADPT.
- 2026-09-25 Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted the new consensus definition of cure for multiple myeloma, presented at the International Myeloma Society (IMS) 23rd Annual Meeting in Glasgow, Scotland, on behalf of IMS and the International Myeloma Working Group (IMWG).
- 2026-09-24 Financial Comparison: Charles River Laboratories International (NYSE:CRL) versus Adaptive Biotechnologies (NASDAQ:ADPT) Adaptive Biotechnologies (NASDAQ: ADPT - Get Free Report) and Charles River Laboratories International (NYSE: CRL - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations. Institutional and Insider Ownership 99.2% of
- 2026-09-22 Adaptive Biotechnologies (NASDAQ:ADPT) Reaches New 1-Year High – Should You Buy? Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) shares hit a new 52-week high during trading on Tuesday. The company traded as high as $28.78 and last traded at $27.86, with a volume of 1458524 shares changing hands. The stock had previously closed at $28.61. Wall Street Analyst Weigh In Several equities research analysts
- 2026-09-17 Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ® Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10 -6 sensitivity now preferred SEATTLE, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted significant updates to the National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma that further establish highly sensitive minimal (or measurable) residual disease (MRD) assessment as an important tool in myeloma care.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 74.2% | 59.7% | 55.6% | 68.7% | 68.1% | |
| Ebit Margin | -17.2% | -82.7% | -124.2% | -105.8% | -134.3% | |
| Ebitda Margin | -10.8% | -71.9% | -111.2% | -94.6% | -125.3% | |
| Operating Profit Margin | -20.6% | -90.8% | -133.3% | -108.0% | -135.4% | |
| Pretax Profit Margin | -21.5% | -89.2% | -132.3% | -108.1% | -134.3% | |
| Continuous Operations Profit Margin | -21.5% | -89.2% | -132.3% | -108.1% | -134.3% | |
| Net Profit Margin | -21.5% | -89.1% | -132.3% | -108.0% | -134.3% | |
| Bottom Line Profit Margin | -21.5% | -89.1% | -132.3% | -108.0% | -134.3% | |
| Current Ratio | 3.339 | 2.894 | 4.660 | 5.120 | 3.539 | |
| Quick Ratio | 3.229 | 2.808 | 4.496 | 4.989 | 3.370 | |
| Solvency Ratio | -0.145 | -0.416 | -0.575 | -0.457 | -0.606 | |
| Cash Ratio | 0.784 | 0.489 | 0.739 | 0.820 | 1.222 | |
| Price To Earnings Ratio | -41.641 | -5.556 | -3.141 | -7.640 | -19.219 | |
| Price To Earnings Growth Ratio | 0.652 | 0.181 | -0.056 | 0.242 | -0.509 | |
| Forward Price To Earnings Growth Ratio | 0.652 | 0.181 | -0.056 | 0.242 | -0.509 | |
| Price To Earnings Diluted Ratio | -41.641 | -5.556 | -3.141 | -7.640 | -19.219 | |
| Price To Earnings Diluted Growth Ratio | 0.652 | 0.181 | -0.056 | 0.242 | -0.509 | |
| Price To Book Ratio | 11.262 | 4.354 | 2.294 | 2.346 | 6.521 | |
| Price To Sales Ratio | 8.896 | 4.932 | 4.155 | 5.876 | 25.517 | |
| Price To Free Cash Flow Ratio | -50.341 | -8.926 | -4.236 | -5.436 | -15.477 | |
| Price To Operating Cash Flow Ratio | -53.581 | -9.270 | -4.526 | -5.919 | -20.435 | |
| Debt To Assets Ratio | 0.547 | 0.166 | 0.149 | 0.126 | 0.121 | |
| Debt To Equity Ratio | 1.282 | 0.441 | 0.320 | 0.233 | 0.185 | |
| Debt To Capital Ratio | 0.562 | 0.306 | 0.243 | 0.189 | 0.156 | |
| Long Term Debt To Capital Ratio | 0.474 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 2.343 | 2.661 | 2.144 | 1.846 | 1.529 | |
| Working Capital Turnover Ratio | 1.399 | 0.705 | 0.440 | 0.500 | 0.339 | |
| Operating Cash Flow Ratio | -0.511 | -0.971 | -1.776 | -1.675 | -1.693 | |
| Operating Cash Flow Sales Ratio | -0.166 | -0.532 | -0.918 | -0.993 | -1.249 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.064 | 1.038 | 1.068 | 1.089 | 1.320 | |
| Debt Service Coverage Ratio | -1.178 | -11.119 | -13.715 | -41.343 | 0.000 | |
| Interest Coverage Ratio | -4.850 | -14.037 | -16.452 | -47.236 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -3.391 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.164 | -1.065 | -1.583 | -1.703 | -1.725 | |
| Capital Expenditure Coverage Ratio | -15.541 | -25.986 | -14.614 | -11.251 | -3.121 | |
| Dividend Paid And Capex Coverage Ratio | -15.541 | -25.986 | -14.614 | -11.251 | -3.121 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -89.595 | -7.177 | -3.916 | -6.317 | -20.228 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 74.2% | ▲14.5% | ▲9.0% |
| Ebit Margin | -17.2% | ▲65.5% | ▲75.6% |
| Ebitda Margin | -10.8% | ▲61.2% | ▲72.0% |
| Operating Profit Margin | -20.6% | ▲70.2% | ▲77.0% |
| Pretax Profit Margin | -21.5% | ▲67.7% | ▲75.6% |
| Continuous Operations Profit Margin | -21.5% | ▲67.7% | ▲75.6% |
| Net Profit Margin | -21.5% | ▲67.6% | ▲75.6% |
| Bottom Line Profit Margin | -21.5% | ▲67.6% | ▲75.6% |
| Current Ratio | 3.338 | ▲0.445 | ▼-0.572 |
| Quick Ratio | 3.229 | ▲0.421 | ▼-0.549 |
| Solvency Ratio | -0.145 | ▲0.272 | ▲0.295 |
| Cash Ratio | 0.784 | ▲0.295 | ▼-0.027 |
| Price To Earnings Ratio | -41.641 | ▼-36.086 | ▼-26.202 |
| Price To Earnings Growth Ratio | 0.652 | ▲0.471 | ▲0.550 |
| Forward Price To Earnings Growth Ratio | 0.652 | ▲0.471 | ▲0.550 |
| Price To Earnings Diluted Ratio | -41.641 | ▼-36.086 | ▼-26.202 |
| Price To Earnings Diluted Growth Ratio | 0.652 | ▲0.471 | ▲0.550 |
| Price To Book Ratio | 11.262 | ▲6.907 | ▲5.906 |
| Price To Sales Ratio | 8.896 | ▲3.964 | ▼-0.979 |
| Price To Free Cash Flow Ratio | -50.342 | ▼-41.415 | ▼-33.458 |
| Price To Operating Cash Flow Ratio | -53.581 | ▼-44.311 | ▼-34.835 |
| Debt To Assets Ratio | 0.547 | ▲0.382 | ▲0.325 |
| Debt To Equity Ratio | 1.282 | ▲0.842 | ▲0.790 |
| Debt To Capital Ratio | 0.562 | ▲0.256 | ▲0.271 |
| Long Term Debt To Capital Ratio | 0.473 | ▲0.473 | ▲0.379 |
| Financial Leverage Ratio | 2.344 | ▼-0.317 | ▲0.239 |
| Working Capital Turnover Ratio | 1.399 | ▲0.694 | ▲0.723 |
| Operating Cash Flow Ratio | -0.511 | ▲0.460 | ▲0.814 |
| Operating Cash Flow Sales Ratio | -0.166 | ▲0.366 | ▲0.606 |
| Free Cash Flow Operating Cash Flow Ratio | 1.064 | ▲0.026 | ▼-0.052 |
| Debt Service Coverage Ratio | -1.178 | ▲9.941 | ▲12.293 |
| Interest Coverage Ratio | -4.850 | ▲9.187 | ▲11.665 |
| Short Term Operating Cash Flow Coverage Ratio | -3.391 | ▼-3.391 | ▼-2.713 |
| Operating Cash Flow Coverage Ratio | -0.164 | ▲0.901 | ▲1.084 |
| Capital Expenditure Coverage Ratio | -15.541 | ▲10.445 | ▼-1.438 |
| Dividend Paid And Capex Coverage Ratio | -15.541 | ▲10.445 | ▼-1.438 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -89.595 | ▼-82.418 | ▼-64.148 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.46B | $882.6M | $707.5M | $1.09B | $3.94B | |
| Enterprise value | $2.67B | $924.1M | $741.2M | $1.11B | $3.91B | |
| EV / Sales | 9.65x | 5.16x | 4.35x | 5.97x | 25.34x | |
| EV / Op. cash flow | -58.15x | -9.71x | -4.74x | -6.02x | -20.29x | |
| EV / Free cash flow | -54.63x | -9.35x | -4.44x | -5.53x | -15.37x | |
| EV / EBITDA | -89.59x | -7.18x | -3.92x | -6.32x | -20.23x | |
| Net debt / EBITDA | -7.04x | -0.32x | -0.18x | -0.10x | 0.14x | |
| Current ratio | 3.34x | 2.89x | 4.66x | 5.12x | 3.54x | |
| Income quality | 0.77x | 0.60x | 0.69x | 0.92x | 0.93x | |
| Graham net-net | -$0 | -$1 | $0 | $1 | $0 | |
| Tax burden | 100.1% | 99.9% | 100.0% | 99.9% | 100.0% | |
| Interest burden | 124.7% | 107.8% | 106.5% | 102.2% | 100.0% | |
| Working capital | $210.3M | $185.7M | $322.2M | $452.4M | $288.9M | |
| Invested capital | $405.7M | $402.5M | $566.6M | $742.4M | $589.4M | |
| Return on assets | -11.6% | -29.6% | -34.1% | -23.4% | -22.4% | |
| Operating ROA | -10.9% | -27.1% | -29.9% | -22.5% | -20.5% | |
| Return on tangible assets | -15.2% | -38.2% | -41.9% | -27.4% | -26.0% | |
| Return on equity | -27.2% | -78.7% | -73.0% | -43.1% | -34.3% | |
| Return on invested capital | -13.1% | -36.0% | -39.0% | -26.5% | -25.7% | |
| Return on capital employed | -13.5% | -36.8% | -39.6% | -26.8% | -25.8% | |
| Earnings yield | -2.4% | -18.1% | -31.8% | -18.4% | -5.3% | |
| Free cash flow yield | -2.0% | -11.2% | -23.6% | -18.4% | -6.5% | |
| Capex / Op. cash flow | -6.4% | -3.8% | -6.8% | -8.9% | -32.0% | |
| Capex / Depreciation | 16.6% | 19.0% | 48.1% | 78.2% | 442.5% | |
| Capex / Sales | 1.1% | 2.0% | 6.3% | 8.8% | 40.0% | |
| SG&A / Sales | 60.4% | 88.0% | 101.3% | 99.4% | 110.1% | |
| R&D / Sales | 33.9% | 57.5% | 71.7% | 76.5% | 92.2% | |
| Stock comp / Sales | 18.6% | 30.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 23.5% | 22.7% | 18.8% | 14.7% | 13.8% | |
| Days sales outstanding | 66d | 85d | 81d | 79d | 41d | |
| Days payables outstanding | 33d | 37d | 37d | 51d | 24d | |
| Operating cycle | 117d | 128d | 151d | 170d | 184d | |
| Cash conversion cycle | 84d | 91d | 114d | 119d | 159d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years